News

“Applied UV Has Filed A New International Patent Application Titled ‘Interchangeable Drain Disinfecting Device With UV Source Irradiation Optimization'” – PatentGrants

https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2022192695

byBenzinga Newsdesk

September 15, 2022

1 minute read

https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2022192695

ViacomCBS, Altice USA Report Renewal Of Distribution Deal, No Terms Disclosed

By Benzinga Newsdesk

Today, 10:44 PM

ViacomCBS Inc. (NASDAQ:VIAC, VIACA)) and Altice USA (NYSE:ATUS) today announced a comprehensive agreement for the continued carriage of ViacomCBS’ leading portfolio of broadcast, entertainment, news and sports

ATUS

TherapeuticsMD Q1 EPS $(4.72) Misses $(4.00) Estimate, Sales $19.33M Beat $17.95M Estimate

By Benzinga Newsdesk

Today, 10:44 PM

TherapeuticsMD (NASDAQ:TXMD) reported quarterly losses of $(4.72) per share which missed the analyst consensus estimate of $(4.00) by 18 percent. This is a 4190.91 percent decrease over losses of $(0.11) per share from

TXMD

This Specialized MDMA Producer Will Provide Psychedelics Exclusively For Canadian Massive Research Organization

By Lara Goldstein

Today, 10:44 PM

A new deal has been signed between PharmAla Biotech Holdings Inc. (CSE: MDMA) and InterVivo Solutions for GMP MDMA and engineering MDMA supply towards research on its impact on neuropsychiatric and neurological diseases.

CSE:MDMA

Otonomy Completes Enrollment In Phase 2 Clinical Trial Of OTO-313 In Tinnitus

By Benzinga Newsdesk

Today, 10:44 PM

Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the completion of patient enrollment in the Phase 2 clinical trial of

OTIC

“Applied UV Has Filed A New International Patent Application Titled ‘Interchangeable Drain Disinfecting Device With UV Source Irradiation Optimization'” – PatentGrants

Related Posts

ViacomCBS, Altice USA Report Renewal Of Distribution Deal, No Terms Disclosed

TherapeuticsMD Q1 EPS $(4.72) Misses $(4.00) Estimate, Sales $19.33M Beat $17.95M Estimate

This Specialized MDMA Producer Will Provide Psychedelics Exclusively For Canadian Massive Research Organization

Otonomy Completes Enrollment In Phase 2 Clinical Trial Of OTO-313 In Tinnitus